Details of the Drug Combination

General Information of Drug Combination (ID: DCCAQT0)

Drug Combination Name

Heparin Bivalirudin

Indication

Disease Entry	Status	REF
Coronary Microvascular Disease	Phase 1	[1]

Component Drugs

Heparin DM4ZP3W

Bivalirudin DMECRX1

Small molecular drug

2D MOL

3D MOL is unavailable

3D MOL

Molecular Interaction Atlas of This Drug Combination

Molecular Interaction Atlas (MIA)

Indication(s) of Heparin

Disease Entry	ICD 11	Status	REF
Aplastic anemia	3A70	Approved	[2]
Bacteremia	1A73	Approved	[2]
Burns	N.A.	Approved	[2]
Coronary heart disease	BA80.Z	Approved	[2]
Deep vein thrombosis	BD71	Approved	[2]
Disseminated intravascular coagulation	3B20	Approved	[2]
Metabolic disorder	5C50-5D2Z	Approved	[2]
Pneumonia	CA40	Approved	[2]
Pulmonary embolism	BB00	Approved	[2]
Venous thrombosis	BA43	Approved	[3]
Coronavirus Disease 2019 (COVID-19)	1D6Y	Investigative	[4]
Diabetic angiopathy	BD53.Y	Investigative	[2]

Indication(s) of Bivalirudin

Disease Entry	ICD 11	Status	REF
Thrombocytopenia	3B64	Approved	[5]

Bivalirudin Interacts with 2 DTT Molecule(s)

DTT Name	DTT ID	UniProt ID	Mode of Action	REF
Coagulation factor IIa (F2)	TT6L509	THRB_HUMAN	Inhibitor	[6]
Trypanosoma Trypanothione reductase (Trypano TPR)	TTRTKPV	TYTR_TRYBB	Inhibitor	[7]
------------------------------------------------------------------------------------

Bivalirudin Interacts with 4 DOT Molecule(s)

DOT Name	DOT ID	UniProt ID	Mode of Action	REF
Myeloperoxidase (MPO)	OTOOXLIN	PERM_HUMAN	Decreases Expression	[8]
C-reactive protein (CRP)	OT0RFT8F	CRP_HUMAN	Decreases Expression	[9]
Proteinase-activated receptor 1 (F2R)	OT4WVWBO	PAR1_HUMAN	Decreases Activity	[10]
Proteinase-activated receptor 4 (F2RL3)	OTUNAKDB	PAR4_HUMAN	Decreases Activity	[10]
------------------------------------------------------------------------------------

Test Results of This Drug Combination in Other Disease Systems

Indication	DrugCom ID	Cell Line	Status	REF
Myocardial Infarction	DC11GZG	N. A.	Phase 1	[11]
Coronary Artery Disease	DCTIJK7	N. A.	Phase 1	[12]
------------------------------------------------------------------------------------

References

1	ClinicalTrials.gov (NCT03537586) A Single Center Diagnostic, Cross-sectional Study of Coronary Microvascular Dysfunction
2	Heparin FDA Label
3	FDA Approved Drug Products from FDA Official Website. 2019. Application Number: (ANDA) 090809.
4	Hypothesis for potential pathogenesis of SARS-CoV-2 infection-a review of immune changes in patients with viral pneumonia. Emerg Microbes Infect. 2020 Dec;9(1):727-732.
5	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 6470).
6	New anticoagulants. Am Heart J. 2001 Aug;142(2 Suppl):S3-8.
7	8-Methoxy-naphtho[2,3-b]thiophen-4,9-quinone, a non-competitive inhibitor of trypanothione reductase. Mem Inst Oswaldo Cruz. 2003 Jun;98(4):565-8.
8	Bivalirudin decreases NO bioavailability by vascular immobilization of myeloperoxidase. J Pharmacol Exp Ther. 2008 Nov;327(2):324-31.
9	The effects of bivalirudin compared with those of unfractionated heparin plus eptifibatide on inflammation and thrombin generation and activity during coronary intervention. Coron Artery Dis. 2005 Sep;16(6):401-5. doi: 10.1097/00019501-200509000-00010.
10	Bivalirudin: a new promising direct antithrombin. Indian Heart J. 2007 May-Jun;59(3):288-94.
11	ClinicalTrials.gov (NCT00433966) Harmonizing Outcomes With Revascularization and Stents in Acute Myocardial Infarction
12	ClinicalTrials.gov (NCT01464671) Angiomax or Unfractionated Heparin for Patients Undergoing Percutaneous Coronary Intervention